Related Experiment Video
Updated: Jun 23, 2026
17:28
Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
Published on: June 17, 2015
What have we learned from pre-clinical juvenile toxicity studies?
1Toxicology/Pathology - Global Preclinical Development, Johnson & Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, Beerse, Belgium. gbailey1@its.jnj.com
Reproductive Toxicology (Elmsford, N.Y.)
|May 19, 2009
Summary
Regulatory changes prioritize juvenile toxicity studies. A review of 39 studies suggests designing these pharmaceutical investigations with a clear scientific rationale to yield meaningful data on drug safety.
Area of Science:
- Pharmacology and Toxicology
- Drug Development
- Regulatory Science
Background:
- Recent regulatory shifts have increased the importance of juvenile toxicity studies in the pharmaceutical sector.
- Standardized study designs are increasingly requested by regulatory agencies, despite variations in drug properties and available data.
- Concerns exist regarding the novelty and predictability of findings from current juvenile toxicity studies.
Purpose of the Study:
- To evaluate the learnings and contributions of 39 juvenile toxicity studies from 10 pharmaceutical companies.
- To clarify the usefulness and data-generating potential of existing study designs.
- To advocate for scientifically rationalized and practically interpretable juvenile toxicity study designs.
Main Methods:
- Analysis of data from 39 juvenile toxicity studies contributed by 10 pharmaceutical companies.
- Discussion of perceptions regarding the novelty and utility of findings from these studies.
- Review of study design elements, including practicality and interpretability of endpoints.
Main Results:
- The review aimed to clarify what has been learned from past studies and assess their contribution to understanding juvenile drug toxicology.
- Identified a need for greater clarity on study designs and their ability to generate meaningful, novel toxicological information.
- Highlighted that findings were often predictable, lacking novel toxicity insights.
Conclusions:
- Juvenile toxicity studies require a strong scientific rationale, focusing on obtaining useful toxicological information.
- Study endpoints must be practical and interpretable to ensure meaningful data generation.
- Appropriately designed studies are crucial for identifying safety/pharmacokinetic issues and informing product labeling.
Related Concept Videos
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:23Toxicity Testing in Animals
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
01:00Drug Toxicity: Overview
Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:24Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...